Photobiomodulation for Macular Degeneration: LIGHTSITE III Data and What It Means for Patients
Dr. Douwes reviews the 24-month LIGHTSITE III trial data on PBM for dry AMD, mechanism, patient selection, dosing protocols, and where this therapy fits in practice.